Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Amarin Corporation plc (“Amarin” or the “Company”) (NasdaqGM: AMRN) common stock during the period between July 9, 2009 and October 15, 2013, inclusive (the “Class Period”).
If you have suffered a net loss from investment in Amarin Corporation plc common stock purchased on or after July 9, 2009, and held through the revelation of negative information on October 16, 2013, as described below, at no cost to you, you may obtain additional information about this lawsuit and your ability to become a lead plaintiff by contacting Brower Piven at www.browerpiven.com, by email at email@example.com, by calling 410/415-6616, or at Brower Piven, A Professional Corporation, 1925 Old Valley Road, Stevenson, Maryland 21153. Attorneys at Brower Piven have combined experience litigating securities and class action cases of over 60 years.
No class has yet been certified in the above action. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff no later than January 3, 2014 and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement and how much of a settlement to accept for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the Company during the Class Period.
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants failure to disclose during the Class Period the true prospects for approval of the Company’s Vascepa drug for the ANCHOR indication by the U.S. Food and Drug Administration (“FDA”). According to the complaint, following an October 16, 2013 vote by an advisory panel to the FDA that Vascepa not be approved for use in a broader patient population until results from an additional study had been analyzed, the value of Amarin shares declined significantly.